Why the study?
Oxidative stress and hypoxia contribute to various cardiovascular diseases, prompting evaluation of the effects of sacubitril/valsartan and empagliflozin on HIF-1α and oxidative stress in cardiomyocytes.
Does empagliflozin and sacubitril/valsartan reduce methotrexate-induced cardiotoxicity in H9c2 rat embryonic cardiomyocytes?
Population
H9c2 rat embryonic cardiomyocyte cells exposed to methotrexate
Comparison
EMPA, S/V, or their combination vs methotrexate alone
Design
In vitro preclinical laboratory study
Follow-up
24, 48 and 72 h
Authors
Loading...
Cell-level effects of S/V and EMPA on HIF-1α; hypothesis-generating and leaves open clinical translation.
Does empagliflozin and sacubitril/valsartan reduce methotrexate-induced cardiotoxicity in H9c2 rat embryonic cardiomyocytes?
Sacubitril/valsartan and empagliflozin demonstrate protective effects against methotrexate-induced cardiotoxicity in H9c2 cardiomyocytes by reducing oxidative stress and hypoxia.
Doğan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: